SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

Jun 24 2024
Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland , June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven

Read more

Build something bigger than your career

Enjoyed learning about life at SOPHiA from our blogs? Here are a few of our open roles

Title Country Department
Junior Algorithm Developer Intern Switzerland Data Science
Junior Information Security Analyst Intern France Regulatory & Quality
Sales Executive / Senior Sales Executive United Kingdom Clinical Sales
Strategic Account Manager - JAPAN Japan Clinical Sales
BioPharma Business Development Expert / Manager Switzerland BioPharma Sales